https://www.taxtmi.com/news?id=47465 Rubicon Research Limited completed an all cash acquisition of a formulations manufacturing facility in the Pithampur SEZ capable of producing steroids, hormones and high potency products, inspected by the US FDA in 2022; the purchase adds a third formulations site, supports capacity expansion, diversification into specialty and drug device combination products, and is intended to strengthen supply chain resilience for regulated markets while the company pursues a proposed IPO subject to regulatory approvals and distribution restrictions. en-us Tue, 24 Jun 2025 18:31:04 +0530 Tue, 24 Jun 2025 18:31:05 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=47465 Rubicon Research Limited completed an all cash acquisition of a formulations manufacturing facility in the Pithampur SEZ capable of producing steroids, hormones and high potency products, inspected by the US FDA in 2022; the purchase adds a third formulations site, supports capacity expansion, diversification into specialty and drug device combination products, and is intended to strengthen supply chain resilience for regulated markets while the company pursues a proposed IPO subject to regulatory approvals and distribution restrictions. News - Tue, 24 Jun 2025 18:31:04 +0530 https://www.taxtmi.com/news?id=47465